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Abstract The precision medicine approach of tailoring treat-
ment to the individual characteristics of each patient or sub-
group has been a great success in monogenic diabetes sub-
types, MODY and neonatal diabetes. This review examines
what has led to the success of a precision medicine approach
in monogenic diabetes (precision diabetes) and outlines pos-
sible implications for type 2 diabetes. For monogenic diabetes,
the molecular genetics can define discrete aetiological sub-
types that have profound implications on diabetes treatment
and can predict future development of associated clinical fea-
tures, allowing early preventative or supportive treatment. In
contrast, type 2 diabetes has overlapping polygenic suscepti-
bility and underlying aetiologies, making it difficult to define
discrete clinical subtypes with a dramatic implication for treat-
ment. The implementation of precision medicine in neonatal
diabetes was simple and rapid as it was based on single clin-
ical criteria (diagnosed <6 months of age). In contrast, in
MODY it was more complex and slow because of the lack
of single criteria to identify patients, but it was greatly assisted
by the development of a diagnostic probability calculator and
associated smartphone app. Experience in monogenic diabe-
tes suggests that successful adoption of a precision diabetes
approach in type 2 diabetes will require simple, quick, easily
accessible stratification that is based on a combination of
routine clinical data, rather than relying on newer technolo-
gies. Analysing existing clinical data from routine clinical
practice and trials may provide early success for precision
medicine in type 2 diabetes.
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GLP-1 Glucagon-like peptide-1
IPEX Immunodysregulation polyendocrinopathy
enteropathy X-linked
PNDM Permanent neonatal diabetes
TNDM Transient neonatal diabetes
Introduction
Precision medicine refers to the tailoring of medical treat-
ment to the individual characteristics of each patient or
subpopulation [1]. Precision diabetes is when a precision
medicine approach is used to improve treatment of pa-
tients with diabetes. This review aims to examine how
precision diabetes has been successfully applied in mono-
genic diabetes and to ask what this can teach us about the
challenges of implementing a precision diabetes approach
in type 2 diabetes. For a detailed discussion of precision
diabetes for type 2 diabetes, please see review by Mark
McCarthy in this issue of Diabetologia [2].
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Overview of the precision medicine approach
in monogenic diabetes
Overview of neonatal diabetes
Genetic causes of neonatal diabetes Neonatal diabetes is
defined as diabetes developed before 6 months of age.
The knowledge that neonatal diabetes has a monogenic
aetiology is based on two strong strands of evidence; first,
patients with permanent diabetes diagnosed <6 months of
age do not have an increased type 1 diabetes genetic sus-
ceptibility. This is in contrast with the high susceptibility
seen when those diagnosed >6 months [3, 4]. Second, 96%
of patients with known ‘neonatal’ monogenic genetic
aetiology are diagnosed with diabetes < 6 months [5, 6].
Before genetic definition was possible, neonatal diabetes
was classified solely on the clinical course of disease as
transient neonatal diabetes (TNDM), permanent neonatal
diabetes (PNDM), or by the specific syndrome when asso-
ciated with other features e.g. Wolcott–Rallison syndrome
or immunodysregulation polyendocrinopathy enteropathy
X-linked (IPEX) syndrome. We now know of 23 different
genetic causes of neonatal diabetes [7, 8].
Genetic diagnosis: impact on diabetes treatment The key
drive for precision diabetes has been the finding that the ge-
netic aetiology strongly influences treatment choice and the
clinical course (Fig. 1) [7]. Approximately 50% of patients
with neonatal diabetes have mutations in the genes encoding
the potassium channel (KCNJ11, ABCC8). These patients
show excellent glucose control with high-dose sulfonylureas
without an increase in hypoglycaemia and glucose variability
[9]. They also show improvements in their neurological func-
tion following sulfonylurea therapy [10, 11]. Patients with
transient neonatal diabetes as a result of 6q24 methylation
abnormalities can be treated with low-dose sulfonylureas
when they relapse (Fig. 1). In contrast, patients with other
neonatal diabetes subtypes require insulin treatment.
Genetic diagnosis: impact on clinical course Another key
benefit of precision medicine is the ability to explain addition-
al clinical abnormalities that are associated with the underly-
ing genetic cause (Fig. 1). These may be already present (e.g.
cardiac defects in patients with GATA6 mutations,
microencephaly in patients with IER3IP1 mutations and gall
bladder and gut atresia in patients with RFX6 mutations), an-
ticipated (e.g. exocrine pancreas deficiency in patients with
mutations in GATA4, GATA6 or PDX1, and remission of tran-
sient diabetes in patients with 6q24 methylation abnormali-
ties) or they may develop later (e.g. hepatic failure and bone
abnormalities in Wolcott–Rallison syndrome or other autoim-
mune conditions with IPEX syndrome) [7].
Early comprehensive genetic testing: a paradigm shift for
managing neonatal diabetes The development in targeted
next-generation DNA sequencing has allowed rapid and com-
prehensive testing of all known genetic aetiology in monogen-
ic diabetes [12]. In parallel, referral time from development of
Diabetes developed 
under 6 months 
of age 
Rapid non-selective 
genetic testing of multiple 
genes simultaneously
(independent of 
clinical features)
Treatment of diabetes
High-dose sulfonylureas – ABCC8, KCNJ11 (50% of all neonatal diabetes)
Low-dose sulfonylureas – 6q24 methylation defect
Explanation of associated clinical features
Heart defects – GATA4, GATA6
Gut and gall bladder atresia – RFX6
Microencephaly – IER3IP1
Hypothyroidism – GLIS3
Anticipated clinical features
Resolution of transient diabetes – ABCC8, KCNJ11, 6q24 
Exocrine pancreas deficiency – HNF1B, GATA4, GATA6, PDX1
Additional autoimmune disease – FOXP3, STAT3
Bone and liver disease – EIF2AK3
Developmental delay – KCNJ11, EIF2AK3, NEUROD1, MNX1, NKX2-2
Early intervention for comorbidities
Support for developmental delay – ABCC6, KCNJ11, others
Early thiamine treatment for anaemia – SLC19A2 
Early bone marrow transplant for severe monogenic autoimmune aetiologies
Fig. 1 The paradigm shift: early non-selective genetic testing for neona-
tal diabetes. The figure shows the benefits of early comprehensive genetic
testing in the management of neonatal diabetes. For example, genotype
may: (1) predict treatment response: e.g. patients with mutations in
KCNJ11/ABCC8 respond well to high-dose sulfonylureas; (2) explain
pre-existing clinical features (e.g. heart defects with GATA4/6 mutation,
microencephaly with IER3IP1mutation and hypothyroidism with GLIS3
mutation); (3) shed light on anticipated clinical abnormalities (e.g.
exocrine pancreas deficiency with mutations in GATA4, GATA6 or
PDX1, and bone and liver disease with EIF2AK3 mutations); (4) lead to
early intervention for co-morbidities, such as early treatment with high
doses of sulfonylureas in KCNJ11-neonatal diabetes to improve the out-
come when the mutation causes severe developmental delay, or early
treatment with thiamine in thiamine-responsive megaloblastic anaemia
(TRMA) neonatal diabetes
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diabetes to genetic testing reduced from 4 years to 7 weeks
between 2004 and 2013 [7]. These two factors have led to a
paradigm shift in the way that we manage neonatal diabetes as
we can now make a rapid and precise genetic diagnosis before
the development of all clinical features (Fig. 1). This can lead to
early appropriate treatment of the diabetes and future planning
for other clinical developments [7]. For example, early diagnosis
of TNDM allows remission to be predicted and planned for, and
knowing that developmental delay is a feature of the genetic
aetiology allows early developmental assessment and support.
Furthermore, early treatment with sulfonylureas inKCNJ11- and
ABCC8-neonatal diabetes probably results in less severe deve-
lopmental delay [11]. In addition, early treatment with thiamine
in thiamine-responsive megaloblastic anaemia (TRMA) neo-
natal diabetes can improve glycaemic control [13]. Finally, for
IPEX and other severe monogenic autoimmune syndromes,
early diagnosis allows consideration for early curative bone
marrow transplantation before patients are too sick [14].
Overview of MODY
Genetic causes ofMODYMODYwas originally defined as a
clinical subgroup of familial diabetes that was diagnosed early
(typically before 25 years of age) but despite this, this condi-
tion was not insulin dependent and showed autosomal domi-
nant inheritance [15, 16]. The initial linkage analysis in large
families led to discovery of the first MODY gene, encoding
glucokinase (GCK) [17, 18]. This was rapidly followed by
discovery of genes encoding hepatic nuclear factor 1 alpha
(HNF1A) [19], hepatic nuclear factor 4 alpha (HNF4A) [20]
and hepatic nuclear factor 1 beta (HNF1B) [21]. Although
other genetic causes have subsequently been described, none
of these are as common as the four genetic causes initially
described [22]. MODY represents between 1.2% and 3.0%
of diabetes diagnosed in children, at least in predominately
white European populations ([11, 12] and reviewed in [23]).
Discrete clinical features of commonMODY subtypes The
discovery of the MODY genes led to the description of dis-
crete clinical courses for different genetic subtypes (Fig. 2).
GCK-MODY shows a stable, raised fasting glucose in con-
trast with the progressive deterioration of glucose over time
observed with transcription factor-linked MODY (HNF1A-,
HNF4A- and HNF1B-MODY; Fig. 2) [6, 24]. Patients with
transcription factor-linked MODY have different associated
features based on their underlying aetiology, such as
Clinical features
Age of diagnosis
Sex
BMI
Duration of diabetes
Treatment
Current treatment
Time to continuous insulin therapy 
HbA1c 
MODY probability calculator
Other useful information
Birthweight
Neonatal complications
Glycosuria
Other clinical features
Biomarkers 
C-peptide >200 pmol/l
Islet autoantibodies negative
MODY genetic testing
HNF1A-MODY
Progressive beta cell dysfunction
Glycosuria
HNF4A-MODY
Progressive beta cell dysfunction
Fetal macrosomia
Neonatal hypoglycaemia 
GCK-MODY
Stable beta cell function
Stable mildly raised glucose 
HNF1B-MODY
Beta cell developmental defect 
Exocrine pancreas deficiency
Other organ developmental defects 
e.g kidney, uterus
Low-dose sulfonylureas No treatment required Insulin
Family history
Parental history of diabetes
Fig. 2 Identification, important clinical features and treatment implica-
tions for common subtypes of MODY. An individual’s clinical features,
treatment needs and parental history of diabetes may be suggestive of
MODY. A MODYprobability calculator can use these features to predict
probability of disease, and this calculation of MODY, plus biomarkers of
disease and other useful clinical information will determine if MODY
genetic testing should be carried out. Genetic testing allows for stratifica-
tion of patients into specific MODY subgroups based on their genotype,
which may be used to identify present and predicted clinical features and
treatment responses. For example, patients with GCK-MODY have a
stable, raised fasting glucose, whereas those with HNF1A-, HNF4A- or
HNF1B-MODY experience progressive deterioration of glucose over
time. Furthermore, glycosuria is a known feature of HNF1A-MODY,
whilst fetal macrosomia and neonatal hypoglycaemia often occur in
HNF4A-MODY, and developmental disorders of the kidney and multiple
other organs in HNF1B-MODY
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glycosuria in HNF1A-MODY, fetal macrosomia and neonatal
hypoglycaemia in HNF4A-MODY, and developmental disor-
ders of the kidney andmultiple other organs inHNF1B-MODY
(Fig. 2) [6]. The majority of genetic testing requires initial clin-
ical selection followed bymolecular genetic testing of either the
most likely gene or a panel of all MODY genes [12].
Differential treatment response in MODY subtypes
Probably the most important clinical feature associated with
precision diabetes in MODYpatients has been the differential
treatment response in discrete genetic groups (Fig. 2). GCK-
MODY patients do not require treatment [24, 25] and do not
respond to either oral agents or low-dose insulin [24, 26]. In
contrast, HNF1A- and HNF4A-MODYpatients can be treated
with low-dose sulfonylureas [6, 27, 28]. Patients who require
additional treatment can have dipeptidyl peptidase-4 (DPP-4)
inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonist
and insulin in addition to sulfonylureas. Patients withHNF1B-
MODY require insulin treatment as the response to sulfonyl-
ureas and other oral medication is limited [29].
Increasing genetic diagnosis of MODY throughout the
world MODY genetic testing is increasing throughout the
world and most developed countries have at least one academ-
ic, health service or commercial laboratory providing mono-
genic diabetes testing. Within the UK, the Exeter laboratory
have gone from ∼50 patients being diagnosed with MODY in
1996 to ∼5000 diagnoses in 2016.
Why has precision medicine in monogenic diabetes
worked well?
Subgroups that are clearly defined by underlying
aetiology
A key feature of monogenic diabetes is that finding a mutation
results in diagnosis of a specific subgroup. These specific
subcategories have the advantage of being non-overlapping
with differential clinical implications (Fig. 3). In addition,
for many monogenic diabetes subtypes, the specific mutation
will determine the clinical outcome because of genotype–phe-
notype relationships. For example, in KCNJ11-neonatal dia-
betes, the mutation severity determines the phenotype [30].
The functional impact of the mutation increases as the pheno-
type changes from TNDM to isolated PNDM, to PNDM with
a neurological phenotype (developmental delay, epilepsy and
neonatal diabetes [DEND]) [30, 31]. As another example,
HNF4A-MODY patients with the p.R114W mutation (found
in ∼15% of HNF4A-MODY patients) have different pheno-
types compared with other HNF4A-MODY patients. They
showed reduced sensitivity to low-dose sulfonylurea treat-
ment, reduced penetrance and no effect on birthweight [32].
In contrast,GCK-MODY is interesting in that it has a uniform
phenotype despite there being considerable functional differ-
ences in mutation severity [26]; this is due to compensation by
overexpression of the normal allele [33].
Large differences in treatment response in monogenic
diabetes
Differences in treatment response can have a large impact in
monogenic diabetes. The best example is the enhanced sensi-
tivity to sulfonylureas in HNF1A-MODY, meaning that pa-
tients may become severely hypoglycaemic if standard doses
are used, and that discontinuing sulfonylureas results in a
marked deterioration in blood glucose (a 5% point reduction
[31 mmol/mol] in HbA1c) [6, 34]. In a randomised trial sulfo-
nylureas led to a fourfold greater reduction of fasting blood
glucose in HNF1A-MODY patients compared with age, BMI
and blood glucose level-matched type 2 diabetes patients [27].
This sensitivity to sulfonylureas was initially identified from
clinical observation and was not predicted from gene function
[34]. In contrast, there is a lack of glycaemic response with oral
hypoglycaemic agents or low-dose insulin in patients with
GCK-MODY [26]. The lack of efficacy of insulin treatment
at a median dose of 0.4 U kg−1 day−1 is also seen in pregnancy
as the birthweight of offspring ofGCK-MODYpatients treated
with insulin and without insulin are similar [35]. Insulin is still
recommended for individuals with GCK-MODY in some cir-
cumstances in pregnancy but even at very high doses, its ability
to lower the mother’s blood glucose levels is limited (reviewed
in [24]). The lack of response to therapy may be predicted
because GCK-MODYpatients have a regulated blood glucose
that is set at a higher level, as a result of insulin and counter-
regulatory hormones being regulated to maintain this elevated
glucose level [24, 36].
High-dose sulfonylurea treatment in potassium channel-
linked neonatal diabetes (ABCC8- and KCNJ11-neonatal dia-
betes) had a massive impact on endogenous insulin secretion
(measured by C-peptide), which increased from an undetect-
able level to the level necessary to maintain glucose at near
normal values [8]. This resulted in an ∼2 percentage point
(22 mmol/mol) improvement in HbA1c in the short term,
which persisted for more than 5 years [9, 37]. Importantly,
the basis for attempting this therapy arose from the knowledge
that the potassium channel is the target of sulfonylureas.
The difficulties of bringing a precision diabetes
approach into monogenic diabetes care
Neonatal diabetes: a success story of rapid implementation
The easy clinical recognition of neonatal diabetes combined
with a dramatic treatment response following precise genetic
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diagnosis led to international guidelines being changed within
2 years after gene discovery [38]. The simple clinical guidance
was issued that diagnostic genetic testing is required for all
patients who developed diabetes before 6 months of age. The
simplicity of this guidance greatly helped towards its rapid
dissemination worldwide. This was further helped by support
from the Wellcome Trust, allowing the Exeter Molecular
Genetics Laboratory to offer free rapid comprehensive genetic
testing throughout the world for patients with neonatal diabe-
tes until at least 2020. This has resulted in over 1700 patients
from 87 countries being tested for neonatal diabetes [7].
MODY: slow uptake into clinical practice
The recognition of MODY has been slow despite MODY
being relatively common, the technology for genetic diagnosis
being available in most countries and clear treatment recom-
mendations having been defined once a diagnosis is made,
both outside and during pregnancy [6, 24]. This is partly be-
cause precision diabetes based on genetic testing is a new
concept for diabetologists; genetics is not a part of routine
clinical training and, traditionally, the speciality of diabetes
emphases are based on treatment rather than diagnosis. In
addition, a major barrier for the dissemination of precision
diabetes in MODY was the lack of single clinical criteria that
can accurately identify all MODY patients. MODY cases
overlap with type 1 and type 2 diabetes patients with regard
to age of onset, BMI, history of parental diabetes, HbA1c
levels and treatment (Fig. 4) [39]. The traditional criteria of
MODY (diabetes diagnosis <25 years, non-insulin treated and
an affected parent) identify only 48% of MODY cases and,
hence, are not sufficiently sensitive to be used alone in clinical
practice [40]. The net result of these barriers is that the major-
ity of MODYpatients are not recognised [40, 41]. In addition,
the cost of the genetic test is an important barrier to imple-
mentation, although early health economic evidence supports
the cost effectiveness of genetic testing for both neonatal dia-
betes and MODY [42, 43].
A solution to diagnosing MODY when there is no single
criterion or threshold
DiagnosingMODY requires a complex multi-dimensional as-
sessment of probability based on more than one clinical crite-
rion. This may be difficult for clinicians but can be easily done
by use of a statistical calculator that uses multiple, but readily
available, clinical information to assess the probability of a
patient having MODY. The ‘MODY Probability Calculator’
was developed by B. Shields and is available without charge
at www.diabetesgenes.org and on the ‘Diabetes Diagnostic’
app for iOS and Android mobile platforms [39]. In a head-to-
head competition, it proved to be as good as clinical experts
with more than two decades of experience working with
MODY (B. Shields, [University of Exeter Medical School,
Exeter, UK] and A. T. Hattersley, personal communication).
The probability calculator works best for patients who are not
insulin treated. For patients who are insulin treated in whom
the diagnosis of MODY is being considered, additional non-
genetic tests (islet autoantibody testing and C-peptide analy-
sis) should be considered as ‘rule-out tests’; the presence of
Monogenic diabetes
Neonatal diabetes
Type 2 diabetes
KCNJ11 INS
PNDMPNDM
High-dose 
sulfonylureas Insulin
MODY
HNF1A GCK
Progressive beta 
Low-dose 
sulfonylureas
Limited implication 
on treatment
No treatment
No discrete
 subtypes
Genetic 
aetiology
Clinical features
Treatment 
Polygenic
cell dysfunction
Stable beta cell 
dysfunction
Fig. 3 Molecular genetics-based approach for precision diabetes in
monogenic and type 2 diabetes. An example of a precision diabetes ap-
proach in monogenic diabetes, in which molecular genetic aetiology de-
fines subgroups that have differential features and treatment implications,
is shown. A similar approach of precision diabetes in polygenic complex
type 2 diabetes has failed to identify clear discrete aetiological subgroups
and associated clinically useful treatment implications
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islet autoantibodies and/or C-peptide <200 pmol/l effectively
rules out MODY [44, 45].
The development of a MODY probability calculator has
proved a very promising first step towards precision diabetes.
The mobile app is widely used (>6000 downloads to date).
This provides a good example of how sophisticated modelling
of a complex diagnostic challenge can be simplified into a simple
tool that uses readily available clinical information. This ap-
proach can greatly help rapid dissemination of precision diabetes.
New technology does not make clinical selection
redundant
Next-generation sequencing has transformed our ability to per-
form genetic testing but it has not removed the need for clinical
selection of patients with possible monogenic diabetes for the
genetic test. It is now possible to test all genes involved in mono-
genic diabetes in a single gene panel test, both quickly and effi-
ciently [7, 12]. This gene panel testing approach identifies ap-
proximately an additional 25% of monogenic patients with less
common causes compared with selected testing of common ge-
netic subtypes [23]. It removes the need to define the likely
genetic aetiology/subgroups prior to testing; however, extra care
is needed when patients are not selected on phenotype as the
prior likelihood of monogenic diabetes is greatly reduced and
so false positive findings become more likely [46]. The easy
access to sequencing technology has led to laboratories (includ-
ing commercial laboratories) offering diagnostic testing for
monogenic diabetes even when they do not have experience of
monogenic diabetes. This has resulted in benign polymorphisms
frequently being reported as disease-causingmutations (e.g. 38%
of reported cases of HNF1A-MODY in Germany had benign
polymorphisms [47]). Clinical selection of patients with potential
monogenic diabetes is still required since, even with improved
technology, next-generation sequencing cannot find a genetic
aetiology in patients who have type 1 or type 2 diabetes.
Precision medicine in type 2 diabetes: comparisons
with monogenic diabetes
Difficulty in defining aetiological subgroups in type 2
diabetes
Defining subgroups using molecular genetic testing in type 2
diabetes is very unlikely to result in discrete aetiological
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Fig. 4 Clinical features of patients with MODYoverlap with type 1 and
type 2 diabetes. Percentage of (a) parent affected by diabetes (in black)
and (b) treatment (diet, white; oral blood glucose lowering agents (OHA),
black; insulin [± OHA], grey). Density plots for (c) age at diagnosis, (d)
HbA1c and (e) BMI (with child values converted to adult equivalent using
reference charts [39]). For (c), (d) and (e), distributions for the four sub-
types of diabetes are shown as: type 1 diabetes, black line; type 2 diabetes,
red line; GCK-MODY, green line; HNF1A-/HNF4A-MODY, blue line.
To convert values for HbA1c in % into mmol/mol, subtract 2.15 and
multiply by 10.929. All graphs are adopted from Shields et al [39] under
the Creative Commons Attribution 4.0 International (CC BY) license
(https://creativecommons.org/licenses/by/4.0) and amended to include
colour
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subgroups because the genetic predisposition is polygenic
rather than monogenic and the clinical phenotype reflects en-
vironmental as well as genetic influences (Fig. 3) [48]. We can
define aetiological subgroups based on physiological features,
such as insulin resistance and beta cell failure. The main prob-
lems of using these categories are that these features change
over time, there is a lack of agreement on optimummethods of
assessment [49] and biochemical assays used in the definitions
are not standardised between laboratories [50, 51]. Similar
problems are seen in latent autoimmune diabetes in adults
(LADA), in which there is a lack of agreement of which islet
autoantibodies to study, variation in the assays used to mea-
sure a specific antibody and varying thresholds for a positive
test [52]. The difficulty in defining subgroups in type 2 diabe-
tes has a major impact on the ability to optimise treatment.
The lack of marked differences in treatment response
in type 2 diabetes
In type 2 diabetes, it is unlikely that differences in treatment
will be as marked as in monogenic diabetes. On average, most
glucose lowering therapies for type 2 diabetes reduce HbA1c
by about 1% (11 mmol/mol) [53]. It is known that there is
considerable variation in treatment response to glucose low-
ering therapy in type 2 diabetes but, to date, there has been no
description of any subgroups that respond with a dramatic 5
percentage point (31 mmol/mol) change in HbA1c, as ob-
served in individuals with HNF1A-MODY. Pharmacogenetic
impacts on treatment responses in type 2 diabetes exist but all
have been small to date (<0.5% [5 mmol/mol] HbA1c) [54].
An alternative approach may involve defining type 2 diabetes
patients who are unlikely to respond to a specific therapy, with
the best example to date being insulin-treated type 2 patients
with islet autoantibodies or low C-peptide who do not respond
to GLP-1 receptor agonists [55].
An alternative approach for precision medicine in type 2
diabetes
The aim of precision medicine is to find subgroups of patients
that have tailored treatment. It does not specify how these
subgroups are defined. The successful examples of monogen-
ic diabetes (and also cancer) have been based on molecular
genetic analysis but, as outlined above, this is unlikely to be
successful in type 2 diabetes and will not be practical to bring
into routine clinical practice in primary care. Therefore, rather
than defining subgroups based on molecular aetiology, we
suggest initial attempts to define subgroups based on differ-
ential treatment response to drugs (Fig. 5). The initial analysis
for identification of this subgroup should use simple clinical
data (e.g. age of diagnosis, sex and BMI) or readily available
biomarkers (e.g. eGFR). This approach has the advantage that
it can develop relatively quickly because of the use of already
available large-scale routine clinical data and subsequently
tested using clinical trial data for currently available drugs.
The aim will be to create a simple calculator that will use
routine clinical information to provide information on the like-
ly HbA1c response and/or risk of adverse effects for available
Simple clinical information
Genetics
Epigenetics
Pharmacogenomics
Physiological biomarkers 
i.e. insulin resistance, 
C-peptide
Probability calculator for
 likely HbA1c response to drugs
BMI     Sex     Age   eGFR
Better response 
to Drug B
Better response 
to Drug A
Intermediate
response to 
Drug A or B
Fig. 5 Treatment response based approach for precision diabetes in type
2 diabetes. We propose to move the focus from defining subgroups based
on molecular aetiology to defining subgroups based on differential treat-
ment response to drugs. The aim will be to create a statistical probability
calculator that will use simple clinical information (e.g. age, BMI, sex,
eGFR etc.) to provide a likely HbA1c response to existing drugs. Large-
scale routine clinical data will be used to develop a statistical model and
that will be validated in already completed clinical trials. Similar ap-
proaches can also be used for a drug’s side effects. The benefits of this
approach are that it will be quick to develop, easy to implement, provide
clinically useful treatment choices and may incorporate future ‘omic’ or
physiological biomarker discoveries
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medications. If successful, this approach will be easy to im-
plement in clinical practice and will also be a platform on
which future pharmacogenetics or ‘omic’ discoveries can
add to [56]. A recent example of the successful implementa-
tion of this approach is the use of sex and BMI data for iden-
tification of patients with a preferential response to
thiazolidinediones (obese female) or sulfonylureas (slimmale)
[57].
Conclusions
Precision diabetes in monogenic diabetes has been an easy
early win but, in contrast, its implementation in type 2 diabetes
will be considerably more difficult. Monogenic diabetes has
the advantage that there are discrete subgroups that are easily
defined by molecular genetics. Frequently, the knowledge of
the biology that results from the aetiological gene being iden-
tified has helped to define likely treatment response. These
early successes have coloured our approach to precision dia-
betes, favouring genomics-based approaches that search for a
single biomarker or a genetic variant with very large effect on
treatment response. However, type 2 diabetes is a polygenic
condition in which environment, as well as genetic predispo-
sition, play a big role. In this case, an approach concentrating
on newer technologies may not be optimum and certainly
examining simple clinical criteria like BMI, sex and age
should be carried out before rushing to molecular technolo-
gies. Finally, one thing that we have learnt from monogenic
diabetes, particularlyMODY, is that even when there is a clear
case, both clinically and economically, for a precision diabetes
approach, implementation may be difficult.
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